Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH-10 in Plaque Psoriasis
NCT00941278Phase 2Completed
- Sponsor
- Provectus Biopharmaceuticals
- Start
- Jul 2009
- Primary completion
- Dec 2009
- Modality
- Hydrogel Systems, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PH-10 in plaque psoriasis, sponsored by Provectus Biopharmaceuticals. Primary endpoints: Treatment Success at 28 days and Incidence of Adverse Experiences at 8 weeks. Started Jul 2009; status: completed.
02
Drugs
PH-10
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00941278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941278.